These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 28565873)

  • 21. MiR-148a suppresses invasion and induces apoptosis of breast cancer cells by regulating USP4 and BIM expression.
    Zhang L; Xing M; Wang X; Cao W; Wang H
    Int J Clin Exp Pathol; 2017; 10(8):8361-8368. PubMed ID: 31966687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effects of Petroselinum Crispum on Estrogen Receptor-positive Benign and Malignant Mammary Cells (MCF12A/MCF7).
    Schröder L; Koch J; Mahner S; Kost BP; Hofmann S; Jeschke U; Haumann J; Schmedt J; Richter DU
    Anticancer Res; 2017 Jan; 37(1):95-102. PubMed ID: 28011479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression of CK-19 gene in circulating tumor cells of blood samples of metastatic breast cancer women.
    Soltani S; Mokarian F; Panjehpour M
    Res Pharm Sci; 2015; 10(6):485-96. PubMed ID: 26779268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1.
    Jiang Q; He M; Ma MT; Wu HZ; Yu ZJ; Guan S; Jiang LY; Wang Y; Zheng DD; Jin F; Wei MJ
    Oncol Rep; 2016 Mar; 35(3):1425-32. PubMed ID: 26707142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
    Kehl KL; Shen C; Litton JK; Arun B; Giordano SH
    Breast Cancer Res Treat; 2016 Jan; 155(1):165-73. PubMed ID: 26706041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
    Xiong R; Patel HK; Gutgesell LM; Zhao J; Delgado-Rivera L; Pham TND; Zhao H; Carlson K; Martin T; Katzenellenbogen JA; Moore TW; Tonetti DA; Thatcher GRJ
    J Med Chem; 2016 Jan; 59(1):219-237. PubMed ID: 26681208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.
    Segovia-Mendoza M; González-González ME; Barrera D; Díaz L; García-Becerra R
    Am J Cancer Res; 2015; 5(9):2531-61. PubMed ID: 26609467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.
    Boukerroucha M; Josse C; ElGuendi S; Boujemla B; Frères P; Marée R; Wenric S; Segers K; Collignon J; Jerusalem G; Bours V
    BMC Cancer; 2015 Oct; 15():755. PubMed ID: 26490435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13.
    Xue J; Chen Z; Gu X; Zhang Y; Zhang W
    Tumour Biol; 2016 Feb; 37(2):1581-90. PubMed ID: 26298724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting effective microRNA target sites in mammalian mRNAs.
    Agarwal V; Bell GW; Nam JW; Bartel DP
    Elife; 2015 Aug; 4():. PubMed ID: 26267216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor mutations and functional consequences for breast cancer.
    Thomas C; Gustafsson JÅ
    Trends Endocrinol Metab; 2015 Sep; 26(9):467-76. PubMed ID: 26183887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of selective estrogen receptor modulators on metabolic homeostasis.
    Xu B; Lovre D; Mauvais-Jarvis F
    Biochimie; 2016 May; 124():92-97. PubMed ID: 26133657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dietary γ-Tocopherol-Rich Mixture Inhibits Estrogen-Induced Mammary Tumorigenesis by Modulating Estrogen Metabolism, Antioxidant Response, and PPARγ.
    Das Gupta S; Sae-tan S; Wahler J; So JY; Bak MJ; Cheng LC; Lee MJ; Lin Y; Shih WJ; Shull JD; Safe S; Yang CS; Suh N
    Cancer Prev Res (Phila); 2015 Sep; 8(9):807-16. PubMed ID: 26130252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen-Related Receptors in Breast Cancer and Prostate Cancer.
    Misawa A; Inoue S
    Front Endocrinol (Lausanne); 2015; 6():83. PubMed ID: 26074877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.
    Fan P; Maximov PY; Curpan RF; Abderrahman B; Jordan VC
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):245-63. PubMed ID: 26052034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baicalein suppresses 17-β-estradiol-induced migration, adhesion and invasion of breast cancer cells via the G protein-coupled receptor 30 signaling pathway.
    Shang D; Li Z; Zhu Z; Chen H; Zhao L; Wang X; Chen Y
    Oncol Rep; 2015 Apr; 33(4):2077-85. PubMed ID: 25672442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global cancer statistics, 2012.
    Torre LA; Bray F; Siegel RL; Ferlay J; Lortet-Tieulent J; Jemal A
    CA Cancer J Clin; 2015 Mar; 65(2):87-108. PubMed ID: 25651787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1.
    Yao Y; Hu J; Shen Z; Yao R; Liu S; Li Y; Cong H; Wang X; Qiu W; Yue L
    J Cell Mol Med; 2015 Apr; 19(4):760-9. PubMed ID: 25639535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer.
    Anbalagan M; Rowan BG
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():264-72. PubMed ID: 25597633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.